# Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

> **NCT03706287** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 62 (estimated)

## Conditions studied

- Lung Cancer Metastatic

## Interventions

- **DRUG:** anlotinib 8mg + AP/PC
- **DRUG:** anlotinib 10mg + AP/PC
- **DRUG:** anlotinib 12mg + AP/PC
- **DRUG:** anlotinib + AP/PC

## Key facts

- **NCT ID:** NCT03706287
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-06
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2020-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706287, "Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03706287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*